ALK EML4-ALK C1156Y

在非小细胞肺癌患者表现出EML4-ALK融合，C1156Y已被证明具有抗环唑天宁的作用。病例报告表明，继发性突变可以调节药物敏感性。eml4-alk c156y/l1196m维持了对环唑替尼的耐药性，而lorlatinib耐药组合eml4-alk c156y/l119f则使肿瘤重新对环唑替尼敏感。
In patients with non-small cell lung cancer exhibiting EML4-ALK fusion, C1156Y has been shown to confer resistance to crizotinib. Case reports indicate that secondary mutations can modulate drug sensitivity. EML4-ALK C1156Y/L1196M maintained crizotinib resistance while the lorlatinib resistant combination EML4-ALK C1156Y/L1198F re-sensitized the tumor to crizotinib treatment.